12/17
04:34 pm
trda
Entrada Therapeutics (NASDAQ:TRDA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Entrada Therapeutics (NASDAQ:TRDA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
12/17
07:00 am
trda
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/11
04:17 pm
trda
Entrada Therapeutics (NASDAQ:TRDA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Entrada Therapeutics (NASDAQ:TRDA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
12/5
04:18 pm
trda
Entrada Therapeutics (NASDAQ:TRDA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Entrada Therapeutics (NASDAQ:TRDA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
12/4
04:30 pm
trda
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/17
09:32 am
trda
Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 Readouts [Seeking Alpha]
Low
Report
Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 Readouts [Seeking Alpha]
11/6
09:01 pm
trda
Entrada Therapeutics (NASDAQ:TRDA) was given a new $13.00 price target on by analysts at Roth Capital.
Low
Report
Entrada Therapeutics (NASDAQ:TRDA) was given a new $13.00 price target on by analysts at Roth Capital.
11/6
07:23 am
trda
Entrada Therapeutics Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
Low
Report
Entrada Therapeutics Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
11/6
07:00 am
trda
Entrada Therapeutics Reports Third Quarter 2025 Financial Results
Low
Report
Entrada Therapeutics Reports Third Quarter 2025 Financial Results
10/28
07:00 am
trda
Entrada Therapeutics to Present at Upcoming Investor Conferences
Low
Report
Entrada Therapeutics to Present at Upcoming Investor Conferences
10/3
03:35 pm
trda
Entrada Therapeutics (NASDAQ:TRDA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Entrada Therapeutics (NASDAQ:TRDA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.